Latest filing published 28 Jun 2018 for Aveo Pharmaceuticals, INC., €340k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Jon Sakoda: trading record in brief
This profile gathers the share dealings of Jon Sakoda across 6 companies, led by Aveo Pharmaceuticals, Inc., Ardelyx, Inc. and Cascadian Therapeutics, Inc. The record holds 22 filings, for trades running from 27 May 2015 to 28 June 2018.
On the open market, the record shows 16 purchases worth €33.1M and 1 sale worth €595k. Purchases outweigh sales by €32.5M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 share grants. So far in 2018, the count stands at 10 purchases and 1 sale.
A typical purchase (the median) is worth €372k. On 16 out of 16 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The record was last updated on 28 June 2018 with an open-market purchase (€340k) in Aveo Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Jon Sakoda
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 187,130 shares@ US$2.1012.9% of flowCommon StockSEC:0001209191-18-039966:1Canonical exit: 26 Sept 2018 (T+90)
- ▲
Same trade as the filing by Growth Equity Opportunities IV, LLC, counted once
11,384 USD29SEC5,295 shares@ US$2.150.4% of flowCommon StockSEC:0001209191-18-039966:0Canonical exit: 25 Sept 2018 (T+90) - 416,666 shares@ US$4.007.3% of flowCommon StockSEC:0001209191-18-034179:0
- 416,667 shares@ US$4.007.3% of flowCommon StockSEC:0001209191-18-034179:1
- ▲
Same trade as the filing by Growth Equity Opportunities IV, LLC, counted once
591 USD29SEC275 shares@ US$2.150.0% of flowCommon StockSEC:0001209191-18-034189:0Canonical exit: 28 Aug 2018 (T+90) - 184,179 shares@ US$2.136.2% of flowCommon StockSEC:0001209191-18-031987:0Canonical exit: 15 Aug 2018 (T+90)
- 20,100 shares@ US$2.140.7% of flowCommon StockSEC:0001209191-18-031987:1Canonical exit: 16 Aug 2018 (T+90)
- 32,200 shares@ US$2.141.1% of flowCommon StockSEC:0001209191-18-031987:2Canonical exit: 19 Aug 2018 (T+90)
- 70,873 shares@ US$2.132.4% of flowCommon StockSEC:0001209191-18-029302:0Canonical exit: 6 Aug 2018 (T+90)
- 203,200 shares@ US$2.467.5% of flowCommon StockSEC:0001209191-18-024539:2Canonical exit: 9 Jul 2018 (T+90)
- 32,100 shares@ US$2.431.2% of flowCommon StockSEC:0001209191-18-024539:1Canonical exit: 8 Jul 2018 (T+90)
- 685,676 shares@ US$2.2423.2% of flowCommon StockSEC:0001209191-18-024539:0Canonical exit: 5 Jul 2018 (T+90)
- 10,882,574 sharesCommon StockSEC:0001209191-18-019375:0
- 1,460,209 shares@ US$0.5008100.0% of flowCommon StockSEC:0001209191-18-013937:0
- 1,818,000 shares@ US$3.30100.0% of flowCommon StockSEC:0001209191-18-012478:0
- 6,000,000 shares@ US$0.5051.4% of flowCommon StockSEC:0001209191-17-023492:0Canonical exit: 26 Jun 2017 (T+90)
- 500,000 shares@ US$13.50100.0% of flowCommon StockSEC:0001209191-16-155945:0Canonical exit: 19 Mar 2017 (T+90)
- ▲
Same trade as the filing by New Enterprise Associates 12, Limited Partnership, counted once
7M USD28SEC763,650 shares@ US$8.7330.9% of flowCommon StockSEC:0001209191-16-133489:1Canonical exit: 16 Oct 2016 (T+90) - 763,651 shares@ US$8.7330.9% of flowCommon StockSEC:0001209191-16-133489:0Canonical exit: 16 Oct 2016 (T+90)
- 500,000 shares@ US$10.0050.0% of flowCommon StockSEC:0001209191-16-091579:0Canonical exit: 12 Apr 2016 (T+90)
- 19,049 shares0Common StockSEC:0001181431-15-007649:0
21 of 14 declarations
